“Characterisation of novel antibodies which are completely silenced with respect to Fc”
“An integrated approach to managing immunogenicity risk and drug immune modulation”
“CD1d-restricted T cells in patients with oesophageal cancer”
“HLA-E-restricted peptides control natural killer cell responses”
“Clinical Immune Monitoring in Gene Therapy, Immuno-Oncology and SARS-CoV-2 Programs”
“Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR”
Understanding and navigating the immune responses to CRISPR-associated nuclease Cas9”
“Antibody responses to viral-vectored coronavirus vaccines”
“Liquid Biopsy using K-Cytof demonstrates a role for Vg9Vd2 T cells as prognostic factor in breast cancer”
“A Novel Cell Therapy for COVID-19 & Potential future Pandemics”
“Pro5® Pentamers and ProT2® Tetramers for tracking antigen-specific T cells”
“Identification and Characterization of Hepatitis B Virus-Specific T cells”
“Induction of SARS-CoV-2 S-specific CD8+ T cells in the lungs of vaccinated mice”
“Engineering T lymphocytes for chronic HBV infection immunotherapy”
“Epitope identification and clinical immune monitoring tools”
“Hepatitis Virus-specific and Bystander CD8+ T Cells in Viral Hepatitis”
“Harnessing Endogenous Antiviral T cell Responses for Control of Cancer”
“Neo-antigenic Potential of Chromosomal Rearrangements in Mesothelioma”
“Epitope identification and clinical immune monitoring in IO programs”
“Syntekabio Bio's Use of Genomic Big Data in Neoantigen Prediction and Discovery”
“Immunogenicity in the Time of COVID-19”
“Protein Engineering for Reduced Immunogenicity”
“SARS-CoV-2 specific T cell Immunity in COVID 19, SARS and Uninfected Controls”
“Tumour Reactive T cell Functional Programming in Human Cancer”
“Understanding SARS-CoV-2 Specific T cell Response During COVID-19 Convalescence”
“Application of Immunogenicity Prediction and Mitigation for Biotherapeutic Development”
“Tracking Dynamic Changes in Tumour Infiltrating Lymphocytes 𝘪𝘯 𝘷𝘪𝘷𝘰”
“Immunogenicity risk assessment of peptide-related impurities: Current Strategies & its Challenges”
“Epitope identification and clinical immune monitoring in immune oncology programs”
“Assessment of MHC class II-restricted epitope prediction in silico”
“Effects of codon optimization on biotherapeutics: Implications for immunogenicity”
“Antiviral T cells derived from the naïve population for patients post-transplant”
“Using peptide-based assays to improve the laboratory diagnosis of Lyme disease”
“Detailed Characterization of Immune Bio-Markers in Cancer Patients”
“Implementation of risk assessment outputs to drive clinical immunogenicity strategy and regulatory filing-related activities”
“An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”
“Dissecting Melanoma Neoantigen Immunity”
“The Challenge of Measuring Antigenic Diversity”
“Chimpanzee Adenoviral vectors: a potent & flexible platform for genetic vaccination”
“Next Generation approaches to enhance the efficacy of SPEAR T-cells”
“How to develop the vaccines of tomorrow”
“Coupled Long Terminal-CRISPR Gene Editing for the Redirection of T cells”
“Gene transfer of MHC II-restricted CMV-specific TCRs for development of immunotherapy”
“Heterologous prime-boost approaches to CD8+ T cell induction”
“Optimizing Adoptive T cell Therapies”
“De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform”
“Epitope identification and clinical immune monitoring in gene therapy and immune oncology program”
“Measuring Host-vs-CAR-T Immune Responses”
“Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A”
“Mechanisms of Immune Modulation by the Gut Microbiome – Implications for Autoimmunity”
“So You Think You Have Mastered Immunity? Cautionary Tales from the Immunology Revolution”
“Immunogenicity Risk Assessment Tool Box for Biologics Drug Development”
“Non-clinical immunogenicity risk assessment of therapeutic proteins”
“In silico prediction of immunogenicity: filling the gaps”
“Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies”
“In Silico and In Vitro Tools to Investigate Increased Immunogenicity Incidence Observed in Combination Therapies”
“Apitopes to induce immune tolerance - mechanism and action”
“Turnover and transformation of T cell clones in retroviral infection and leukaemia”
“Identifying T & B Cell autoantigen epitopes in Autoimmune Membranous Nephropathy”
“DUSP10 in inflammation and cancer”
“Using synthetic antibody libraries to overcome poor immunogenicity”
“Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children”
“Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV”
“Impact of protein aggregates from biopharmaceuticals on dendritic cells”
“Mammalian Display for TCR discovery & Phosphopeptide neoantigens as targets”
“Low Immunogenicity of Avelumab, An Immune Checkpoint Inhibitor Demonstrating Antitumor Activity”
“Long-term in vivo anti-tumour efficacy of KY1044 (anti-ICOS) as monotherapy and in combination with anti-PD-L1”
“CD8+ T cell recognition of unusual and unnatural peptide epitopes”
“Personalized Cancer Vaccines”
“Host microbe interactions in the intestine: New therapeutic strategies in IBD”
“Host Cell Proteins and Immunogenicity”
“The use of immunogenicity risk assessment tools for lead optimization of biologics”
“Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation”
“Non-clinical Assessments of Immunogenicity”
“DP-C016, a phosphoTau vaccine for the treatment of tauopathies”
“Epitope identification and clinical immune monitoring in immune oncology programmes”
“Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences”
“Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes”
“Specificity and phenotype of pre-existing T cells against therapeutic proteins”
“Immune complexes modulate immune highways and DC trafficking”
“Therapeutic Cancer Vaccines”
“Immunogenicity assessment for Affibody-Fc fusion therapeutics”
“Applying in vitro immunogenicity assays to predicts clinical immunogenicity”
“Analysis of peripheral T cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens”
“Display of foreign surface antigens on baculovirus as pseudotyped viruses for immunological studies and applications”
“Applying mechanism based computational models to CTL epitope prediction”
“Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options”
“Precision Medicine in Transplantation - immune monitoring for the discrimination of GVHD, rejection and CMV infection”
“Understanding the immune response to EBOV during acute disease and in EVD survivors”
“Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms”
“Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”
“Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”
“Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”
“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”
“Immunological biomarkers in Allergy Immunotherapy”
“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”
“Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”
“Combination immunotherapy and vaccines in cancer”
“Tregs -ready for the clinic”
“Vaccines for Prevention of Breast Cancer”
“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”
“A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”
“Ion channel decorated liposomes: therapeutic potential and immunogenicity”
“Switching off immunity: the mechanism of antigen-specific immunotherapy”
“Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”
“Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”
“Vaccines, adjuvants, and autoimmunity”
“Tolerance can be induced in the adult immune system”
“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”
“Contribution of ex vivo assays to immunogenicity risk assessment”
“Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”
“Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”
“Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”
“Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”
“ABIRISK Developments and Challenges: Perspectives from Year 2”
“Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”
“Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes”
“Drug Immunogenicity: Lessons Learnt from Interferon-beta”
“XTEN in Blood Factor Engineering”
“Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”
“B Cell Selection and Survival: First Order Consideration for Immunogenicity”
“Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”
“Immunologic Endpoints for Guiding Biologic Drug Development”
“Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for "First-Man" Studies”
“Assessing and Modulating Immune Responses to AVV Vectors in Humans”
“Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management”
“Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”
“Mastering Immunity: ProStorm™ Cytokine Release Assay”
“MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”
“Immunogenicity of biotherapeutics: Why do we care and where do we stand?”
“CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”
“Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”
“Pre-Clinical Risk Assesment Using Innovative Technologies”
“Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”
